These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26435038)

  • 1. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
    Ofran Y; Leiba R; Ganzel C; Saban R; Gatt M; Ram R; Arad A; Bulvik S; Hellmann I; Gino-Moor S; Zuckerman T; Hoffman R; Horowitz N; Lavi N; Ringelstein S; Henig I; Hayun M; Rowe JM
    Am J Hematol; 2015 Dec; 90(12):1159-64. PubMed ID: 26435038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
    Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?
    Ofran Y
    Curr Opin Hematol; 2016 Mar; 23(2):108-14. PubMed ID: 26717195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
    Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.
    England JT; Saini L; Hogge D; Forrest D; Narayanan S; Power M; Nevill T; Kuchenbauer F; Hudoba M; Szkotak A; Brandwein J; Sanford D
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e427-e436. PubMed ID: 32201130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
    Norkin M; Chang M; An Q; Leather H; Katragadda L; Li Y; Moreb JS; May WS; Brown RA; Hsu JW; Hiemenz JW; Wingard JR; Cogle CR
    Leuk Res; 2016 Jul; 46():69-73. PubMed ID: 27132034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
    Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.
    Grosicki S; Holowiecki J; Giebel S; Kyrcz-Krzemien S; Kuliczkowski K; Kielbinski M; Skotnicki AB; Piatkowska-Jakubas B; Hellmann A; Wierzbowska A; Stella-Holowiecka B; Zdziarska B; Calbecka M
    Am J Hematol; 2011 May; 86(5):437-9. PubMed ID: 21465518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
    Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
    Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.
    Covut F; Gupta D; Pinto R; Dambrosio N; El Jurdi N; Meyerson H; Ueda M; Kolk M; Creger R; Metheny L; Cooper BW; Caimi PF; Malek E; Otegbeye F; Lazarus HM; De Lima M; Tomlinson BK
    Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):73-82. PubMed ID: 30528848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
    Dick FR; Burns CP; Weiner GJ; Heckman KD
    Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
    Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
    Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction.
    Ratei R; Basso G; Dworzak M; Gaipa G; Veltroni M; Rhein P; Biondi A; Schrappe M; Ludwig WD; Karawajew L;
    Leukemia; 2009 Mar; 23(3):528-34. PubMed ID: 19020543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new prognostic stratification for patients with acute myeloid leukemia].
    Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
    Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34 immunohistochemistry in bone marrow biopsies for early response assessment in acute myeloid leukemia.
    Jain S; Mahapatra M; Pati HP
    Int J Lab Hematol; 2015 Dec; 37(6):746-51. PubMed ID: 26248894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.
    Ismail MM; Abdulateef NAB
    Int J Hematol; 2017 Apr; 105(4):453-464. PubMed ID: 27910003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
    Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.
    Liso V; Albano F; Pastore D; Carluccio P; Mele G; Lamacchia M; Mestice A; Specchia G
    Haematologica; 2000 Dec; 85(12):1285-90. PubMed ID: 11114136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.